GlobeNewsWire
05 Mar 2026, 21:05 UTC · 36w ago
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
Impact · against what's priced in
NextCure provides a concrete catalyst for Q2 2026 with the expected release of SIM0505 Phase 1 dose escalation data. The aggressive expansion of trial sites and the initiation of enrollment for platinum-resistant ovarian cancer indicate a push to accelerate the development timeline of its lead ADC asset.
- NXTC+0.50
No priced-in read yet





